WO2000035481A3 - Composition immunogene polyvalente contenant une composition de sous-unite de rsv et une preparation d'influenzavirus - Google Patents

Composition immunogene polyvalente contenant une composition de sous-unite de rsv et une preparation d'influenzavirus Download PDF

Info

Publication number
WO2000035481A3
WO2000035481A3 PCT/CA1999/001194 CA9901194W WO0035481A3 WO 2000035481 A3 WO2000035481 A3 WO 2000035481A3 CA 9901194 W CA9901194 W CA 9901194W WO 0035481 A3 WO0035481 A3 WO 0035481A3
Authority
WO
WIPO (PCT)
Prior art keywords
influenza virus
virus preparation
composition
protein
multivalent immunogenic
Prior art date
Application number
PCT/CA1999/001194
Other languages
English (en)
Other versions
WO2000035481A2 (fr
Inventor
George A Cates
Suryaprakash Sambhara
David Burt
Michel H Klein
Original Assignee
Connaught Lab
George A Cates
Suryaprakash Sambhara
David Burt
Michel H Klein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Connaught Lab, George A Cates, Suryaprakash Sambhara, David Burt, Michel H Klein filed Critical Connaught Lab
Priority to NZ512980A priority Critical patent/NZ512980A/en
Priority to AU15442/00A priority patent/AU769992B2/en
Priority to US09/868,177 priority patent/US7169395B1/en
Priority to DE69940406T priority patent/DE69940406D1/de
Priority to JP2000587800A priority patent/JP4021146B2/ja
Priority to EP99957825A priority patent/EP1140164B1/fr
Priority to MXPA01006214A priority patent/MXPA01006214A/es
Priority to CA002355270A priority patent/CA2355270A1/fr
Publication of WO2000035481A2 publication Critical patent/WO2000035481A2/fr
Publication of WO2000035481A3 publication Critical patent/WO2000035481A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Compositions immunogènes destinées à être administrées aux adultes, notamment aux personnes âgées, afin de les protéger contre les maladies provoquées par le virus respiratoire syncytial et par l'Influenzavirus. Les compositions comprennent une quantité immunogène d'un mélange constitué de la protéine de fusion (F), de la protéine de fixation (G) et de la protéine de matrice (M) du RSV purifiées et d'une quantité immunogène d'une préparation d'Influenzavirus non virulent. Les différents composants de la composition, formulés sous forme de vaccin destiné à l'administration in vivo, n'interfèrent pas entre eux pour ce qui est de l'antigénicité. Les compositions immunogènes peuvent contenir en outre un adjuvant.
PCT/CA1999/001194 1998-12-17 1999-12-16 Composition immunogene polyvalente contenant une composition de sous-unite de rsv et une preparation d'influenzavirus WO2000035481A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
NZ512980A NZ512980A (en) 1998-12-17 1999-12-16 Multivalent immunogenic composition containing RSV subunit composition and influenza virus preparation
AU15442/00A AU769992B2 (en) 1998-12-17 1999-12-16 Multivalent immunogenic composition containing RSV subunit composition and influenza virus preparation
US09/868,177 US7169395B1 (en) 1998-12-17 1999-12-16 Multivalent immunogenic composition containing RSV subunit composition and influenza virus preparation
DE69940406T DE69940406D1 (de) 1998-12-17 1999-12-16 Ine rsv untereinheit zusammensetzung und ein influenzavirus präparat enthält
JP2000587800A JP4021146B2 (ja) 1998-12-17 1999-12-16 Ｒｓｖサブユニット成分およびインフルエンザウイルス調製物を含む多価免疫原性組成物
EP99957825A EP1140164B1 (fr) 1998-12-17 1999-12-16 Composition immunogene polyvalente contenant une composition de sous-unite de rsv et une preparation d'influenzavirus
MXPA01006214A MXPA01006214A (es) 1998-12-17 1999-12-16 Composicion inmunogenica multivalente que contiene una preparacion de virus de influenza y una composicion de subunidad del virus sincicial respiratorio.
CA002355270A CA2355270A1 (fr) 1998-12-17 1999-12-16 Composition immunogene polyvalente contenant une composition de sous-unite de rsv et une preparation d'influenzavirus

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21377098A 1998-12-17 1998-12-17
US09/213,770 1998-12-17

Publications (2)

Publication Number Publication Date
WO2000035481A2 WO2000035481A2 (fr) 2000-06-22
WO2000035481A3 true WO2000035481A3 (fr) 2000-10-26

Family

ID=22796441

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1999/001194 WO2000035481A2 (fr) 1998-12-17 1999-12-16 Composition immunogene polyvalente contenant une composition de sous-unite de rsv et une preparation d'influenzavirus

Country Status (10)

Country Link
US (3) US7169395B1 (fr)
EP (1) EP1140164B1 (fr)
JP (2) JP4021146B2 (fr)
AT (1) ATE422364T1 (fr)
AU (1) AU769992B2 (fr)
CA (1) CA2355270A1 (fr)
DE (1) DE69940406D1 (fr)
MX (1) MXPA01006214A (fr)
NZ (1) NZ512980A (fr)
WO (1) WO2000035481A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1305043A2 (fr) * 2000-07-31 2003-05-02 Aventis Pasteur Limited Vaccin contre le virus respiratoire syncytial
KR101251902B1 (ko) 2003-02-25 2013-04-08 메디뮨 엘엘씨 인플루엔자 백신 조성물의 제조 방법
US20060110406A1 (en) 2003-02-25 2006-05-25 Medimmune Vaccines, Inc. Refrigerator-temperature stable influenza vaccine compositions
US20160000902A1 (en) * 2003-07-11 2016-01-07 Novavax, Inc. Combination vaccine for respiratory syncytial virus and influenza
KR101230187B1 (ko) * 2004-10-06 2013-02-07 메디뮨 엘엘씨 냉장 온도 안정성 인플루엔자 백신 조성물
WO2009029695A1 (fr) * 2007-08-28 2009-03-05 Baxter International Inc. Procédé pour produire des vaccins viraux
AU2009227674C1 (en) 2008-03-18 2015-01-29 Seqirus UK Limited Improvements in preparation of influenza virus vaccine antigens
NZ601345A (en) 2008-10-16 2014-05-30 Univ Dalhousie Combination adjuvant formulation
WO2011011390A1 (fr) * 2009-07-20 2011-01-27 Novavax, Inc. Protéines ha recombinantes purifiées du virus de la grippe
EP2475385A1 (fr) 2009-09-10 2012-07-18 Novartis AG Vaccins combinés contre les maladies des voies respiratoires
JP2014520805A (ja) 2011-07-06 2014-08-25 ナノバイオ コーポレーション ヒト呼吸器合胞体ウイルスワクチン
WO2013036907A1 (fr) 2011-09-09 2013-03-14 Nanobio Corporation Vaccin sous-unitaire contre le virus respiratoire syncytial (rsv) en nano-émulsion
EP2953642A1 (fr) * 2013-02-11 2015-12-16 Novavax, Inc. Vaccin combiné pour le virus respiratoire syncytial et la grippe
US10080792B2 (en) 2013-09-23 2018-09-25 Engen Bio, Inc. Influenza vaccine and therapy
CN104436157A (zh) 2013-09-23 2015-03-25 恩金生物有限公司 流感疫苗和治疗
US11576960B2 (en) * 2018-03-30 2023-02-14 Georgia State University Research Foundation, Inc. Respiratory syncytial virus (RSV) vaccines
AU2020275455A1 (en) * 2019-05-15 2021-12-09 Janssen Vaccines & Prevention B.V. Co-administration of seasonal influenza vaccine and an adenovirus based respiratory syncytial virus vaccine

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995034308A2 (fr) * 1994-06-16 1995-12-21 Connaught Laboratories Limited Compositions d'adjuvant comprenant un sel mineral et un autre compose immunostimulateur
US5494673A (en) * 1993-07-12 1996-02-27 Virus Research Institute Phosphazene polyelectrolytes as immunoadjuvants
WO1996033738A1 (fr) * 1995-04-28 1996-10-31 Franklin Volvovitz Vaccins antiviraux ameliores
WO1998002457A1 (fr) * 1996-07-12 1998-01-22 Connaught Laboratories Limited Preparation de vaccin de sous-unites contre le virus syncytial respiratoire

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022726A (en) * 1992-02-03 2000-02-08 Palese; Peter Genetically engineered attenuated viruses
US5762939A (en) * 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
US20030072774A1 (en) 1994-06-10 2003-04-17 Diane M. Gajewczyk Proteinaceous adjuvants
US5612037A (en) 1994-07-26 1997-03-18 Connaught Laboratories, Inc. Influenza virus subunit conjugates
US5824536A (en) * 1994-08-23 1998-10-20 St. Jude Children's Research Hospital Influenza virus replicated in mammalian cell culture and vaccine production
US5646033A (en) 1994-11-30 1997-07-08 Dyncorp African green monkey kidney cell lines useful for maintaining viruses and for preparation of viral vaccines
US20020136739A1 (en) * 1996-07-12 2002-09-26 Cates George A. Subunit respiratory syncytial virus preparation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5494673A (en) * 1993-07-12 1996-02-27 Virus Research Institute Phosphazene polyelectrolytes as immunoadjuvants
WO1995034308A2 (fr) * 1994-06-16 1995-12-21 Connaught Laboratories Limited Compositions d'adjuvant comprenant un sel mineral et un autre compose immunostimulateur
WO1996033738A1 (fr) * 1995-04-28 1996-10-31 Franklin Volvovitz Vaccins antiviraux ameliores
WO1998002457A1 (fr) * 1996-07-12 1998-01-22 Connaught Laboratories Limited Preparation de vaccin de sous-unites contre le virus syncytial respiratoire

Also Published As

Publication number Publication date
WO2000035481A2 (fr) 2000-06-22
EP1140164B1 (fr) 2009-02-11
NZ512980A (en) 2003-07-25
JP4021146B2 (ja) 2007-12-12
DE69940406D1 (de) 2009-03-26
MXPA01006214A (es) 2004-09-06
US20060159700A1 (en) 2006-07-20
JP2002532435A (ja) 2002-10-02
CA2355270A1 (fr) 2000-06-22
US20080248057A1 (en) 2008-10-09
ATE422364T1 (de) 2009-02-15
US7169395B1 (en) 2007-01-30
AU769992B2 (en) 2004-02-12
JP2007031452A (ja) 2007-02-08
EP1140164A2 (fr) 2001-10-10
AU1544200A (en) 2000-07-03

Similar Documents

Publication Publication Date Title
WO2000035481A3 (fr) Composition immunogene polyvalente contenant une composition de sous-unite de rsv et une preparation d'influenzavirus
WO2000062800A3 (fr) Vaccins
WO2006085983A3 (fr) Adjuvants viraux
DE69818707D1 (de) Chitosan und influenza-antigen(e) enthaltende impfstoff-zubereitungen zur verabreichung durch eine mukosa
NZ323973A (en) Vaccine compositions for intranasal administration comprising chitosan and use thereof
WO2002028422A3 (fr) Vaccin
AU3431197A (en) Subunit respiratory syncytial virus vaccine preparation
HUP0401606A2 (hu) West Nile vakcina
EP1206189A4 (fr) Formulations de vaccins antirotavirus
EP2275121A3 (fr) Vaccins contre le streptococcus pneumoniae à base de protéine
WO2002087494A3 (fr) Nouveau vaccin
CA2302833A1 (fr) Peptides derives de la proteine d'attachement (g) du virus respiratoire syncytial bovin
WO2002100340A3 (fr) Vaccin ameliore contre l'anthrax
ZA959729B (en) Immunogenic compositions
WO2002009749A3 (fr) Vaccin contre le virus respiratoire syncytial
WO2000062802A3 (fr) Vaccin
HK1138516A1 (en) Parenteral vaccine formulations and uses thereof
GR3026619T3 (en) Inactivated respiratory syncytial viral vaccines
EP1905449A3 (fr) Composition adjuvante continant une saponine et un oligonucleotide immunostimulateur
CA2331086A1 (fr) Vaccin contre l'hepatite
BR9909076A (pt) Vìrus atenuado do sarampo, recombinantemente gerado, isolado, vìrus do sarampo, vìrus sincicial respiratório humano (rsv), subgrupo b, atenuado, recombinantemente gerado, isolado, o rsv, subgrupo b, vacina processo para imunização de um indivìduo para induzir proteção contra vìrus do sarampo, processo para imunização de um indivìduo para induzir proteção contra o rsv, subgrupo b, composição, processo para produção de vìrus do sarampo infeccioso atenuado, processo para produção de rsv infeccioso atenuado subgrupo b
WO2003022878A3 (fr) Preparation vaccinale sous-unitaire contre le virus respiratoire syncytial
BR0014246A (pt) Utilização de uma proteìna ompa de enterobactéria, ou um de seus fragmentos, associada a um peptìdeo imunogênico derivado do vìrus respiratório sincicial
CA2378862A1 (fr) Vaccin a constituants multiples pour lutter contre la maladie causee par hemophilus influenzae et moraxella catarrhalis
WO2002053184A3 (fr) Utilisations de composes polycationiques

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2000 15442

Country of ref document: AU

Kind code of ref document: A

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2355270

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2355270

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2000 587800

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/006214

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 512980

Country of ref document: NZ

Ref document number: 1999957825

Country of ref document: EP

Ref document number: 15442/00

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1999957825

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 09868177

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 15442/00

Country of ref document: AU